ZA201205375B - Methods and compositions for improved nerve conduction velocity - Google Patents
Methods and compositions for improved nerve conduction velocityInfo
- Publication number
- ZA201205375B ZA201205375B ZA2012/05375A ZA201205375A ZA201205375B ZA 201205375 B ZA201205375 B ZA 201205375B ZA 2012/05375 A ZA2012/05375 A ZA 2012/05375A ZA 201205375 A ZA201205375 A ZA 201205375A ZA 201205375 B ZA201205375 B ZA 201205375B
- Authority
- ZA
- South Africa
- Prior art keywords
- compositions
- methods
- nerve conduction
- conduction velocity
- improved nerve
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 230000007830 nerve conduction Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29637510P | 2010-01-19 | 2010-01-19 | |
| PCT/AU2011/000051 WO2011088504A1 (en) | 2010-01-19 | 2011-01-19 | Methods and compositions for improved nerve conduction velocity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201205375B true ZA201205375B (en) | 2013-09-25 |
Family
ID=44306296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2012/05375A ZA201205375B (en) | 2010-01-19 | 2012-07-18 | Methods and compositions for improved nerve conduction velocity |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9095587B2 (enExample) |
| EP (1) | EP2525795B1 (enExample) |
| JP (2) | JP6232184B2 (enExample) |
| CN (2) | CN102821765A (enExample) |
| AU (1) | AU2011207104C1 (enExample) |
| CA (1) | CA2787173C (enExample) |
| ES (1) | ES2560327T3 (enExample) |
| NZ (1) | NZ601383A (enExample) |
| WO (1) | WO2011088504A1 (enExample) |
| ZA (1) | ZA201205375B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE028620T2 (en) | 2010-07-21 | 2016-12-28 | Novartis Ag | Tetrahydroisoquinoline derivative salt and solvates |
| US10391331B2 (en) * | 2011-03-29 | 2019-08-27 | Biolyst, Llc. | Systems and methods for use in treating sensory impairment |
| PL2800738T3 (pl) | 2012-01-06 | 2020-10-19 | Novartis Ag | Związki heterocykliczne i sposoby ich stosowania |
| PT2807171T (pt) | 2012-01-25 | 2020-11-03 | Novartis Ag | Compostos heterocíclicos e métodos para a sua utilização |
| NZ627560A (en) | 2012-01-25 | 2016-08-26 | Novartis Ag | Heterocyclic piperazine compounds and methods for their use |
| CN105358532B (zh) * | 2013-07-08 | 2019-07-23 | 诺华股份有限公司 | 杂环化合物和它们的使用方法 |
| JP6667551B2 (ja) | 2015-01-13 | 2020-03-18 | ノバルティス アーゲー | アンジオテンシンｉｉ２型拮抗薬としてのピロリジン誘導体 |
| WO2016142867A1 (en) | 2015-03-12 | 2016-09-15 | Novartis Ag | Heterocyclic compounds and methods for their use |
| CN106478502B (zh) * | 2015-08-29 | 2021-04-27 | 上海翰森生物医药科技有限公司 | 1,2,3,4-四氢异喹啉衍生物、其制备方法和应用 |
| EP3620454B1 (en) | 2017-06-09 | 2021-05-05 | Shandong Danhong Pharmaceutical Co., Ltd. | Carboxylic acid derivative as at2r receptor antagonist |
| CN112585120B (zh) * | 2018-11-02 | 2022-11-11 | 山东丹红制药有限公司 | 一种血管紧张素ii受体2拮抗剂的盐型、晶型及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5091390A (en) | 1990-09-20 | 1992-02-25 | E. I. Du Pont De Nemours And Company | Treatment of CNS disorders with 4,5,6,7-tetrahydro-1H-imidazo (4,5-)-pyridines and analogs |
| CA2132544C (en) * | 1992-04-13 | 2005-10-18 | Frank Carey | Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy |
| US5246943A (en) | 1992-05-19 | 1993-09-21 | Warner-Lambert Company | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties |
| US5236934A (en) | 1992-08-26 | 1993-08-17 | E. I. Du Pont De Nemours And Company | 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders |
| GB2337701A (en) * | 1998-05-26 | 1999-12-01 | United Medical And Dental Schools Of Guys St Thomas Hospitals | Treatment of ischemia with an angiotensin II antagonist |
| EP1830869B1 (en) * | 2004-12-24 | 2013-05-22 | Spinifex Pharmaceuticals Pty Ltd | Method of treatment or prophylaxis |
| JP5230595B2 (ja) * | 2006-03-20 | 2013-07-10 | スピニフェクス ファーマシューティカルズ ピーティーワイ リミテッド | 炎症性疼痛の治療または予防の方法 |
| US7828840B2 (en) | 2007-11-15 | 2010-11-09 | Med Institute, Inc. | Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists |
-
2011
- 2011-01-19 US US13/522,228 patent/US9095587B2/en not_active Expired - Fee Related
- 2011-01-19 CA CA2787173A patent/CA2787173C/en not_active Expired - Fee Related
- 2011-01-19 WO PCT/AU2011/000051 patent/WO2011088504A1/en not_active Ceased
- 2011-01-19 EP EP11734246.9A patent/EP2525795B1/en active Active
- 2011-01-19 JP JP2012549209A patent/JP6232184B2/ja not_active Expired - Fee Related
- 2011-01-19 AU AU2011207104A patent/AU2011207104C1/en not_active Ceased
- 2011-01-19 NZ NZ60138311A patent/NZ601383A/en not_active IP Right Cessation
- 2011-01-19 CN CN2011800145791A patent/CN102821765A/zh active Pending
- 2011-01-19 CN CN201711036658.8A patent/CN107744519A/zh active Pending
- 2011-01-19 ES ES11734246.9T patent/ES2560327T3/es active Active
-
2012
- 2012-07-18 ZA ZA2012/05375A patent/ZA201205375B/en unknown
-
2016
- 2016-04-01 JP JP2016073914A patent/JP2016155846A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HK1176554A1 (en) | 2013-08-02 |
| AU2011207104C1 (en) | 2015-10-08 |
| JP2016155846A (ja) | 2016-09-01 |
| AU2011207104B2 (en) | 2015-07-02 |
| ES2560327T3 (es) | 2016-02-18 |
| CN102821765A (zh) | 2012-12-12 |
| AU2011207104A1 (en) | 2012-07-26 |
| EP2525795B1 (en) | 2015-10-21 |
| EP2525795A1 (en) | 2012-11-28 |
| CA2787173A1 (en) | 2011-07-28 |
| NZ601383A (en) | 2014-07-25 |
| CA2787173C (en) | 2018-05-01 |
| US9095587B2 (en) | 2015-08-04 |
| EP2525795A4 (en) | 2013-07-24 |
| JP6232184B2 (ja) | 2017-11-15 |
| WO2011088504A1 (en) | 2011-07-28 |
| US20130131103A1 (en) | 2013-05-23 |
| JP2013517300A (ja) | 2013-05-16 |
| CN107744519A (zh) | 2018-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL224390B (en) | Compositions and methods for targeted thermal modulation | |
| ZA201205375B (en) | Methods and compositions for improved nerve conduction velocity | |
| GB201218752D0 (en) | Mineral complex, compositions thereof, and methods of using the same | |
| PH12013500698A1 (en) | Hair-mending compositions and associated methods | |
| ZA201402734B (en) | Collector compositions and methods of using the same | |
| EP2611822A4 (en) | COMPOSITIONS FOR IDENTIFICATION OF NERVES AND METHOD FOR THEIR USE | |
| PT3366143T (pt) | Composições e métodos probióticos | |
| PT3636274T (pt) | Composições para modular a atividade das citocinas gama-c | |
| ZA201602366B (en) | Compositions and methods for antibodies targeting epo | |
| GB201315350D0 (en) | Methods and compositions | |
| ZA201205965B (en) | Methods and compositions for applying moxifloxacin to the ear | |
| GB201018650D0 (en) | Methods and compositions | |
| ZA201308892B (en) | Compositions and methods | |
| GB201315347D0 (en) | Methods and compositions | |
| GB2478399B (en) | Toner compositions and methods | |
| GB201004450D0 (en) | Compounds and methods relating thereto | |
| GB201010083D0 (en) | Compositions and methods | |
| GB201018651D0 (en) | Methods and compositions | |
| GB201009767D0 (en) | Compositions and methods | |
| GB201116340D0 (en) | Compositions and methods | |
| GB201003741D0 (en) | Methods and therapeutic compositions | |
| GB201107454D0 (en) | Compositions and uses | |
| GB201101924D0 (en) | Compositions and uses | |
| GB201120470D0 (en) | Compositions and uses thereof | |
| AU2011903938A0 (en) | Therapeutic methods and compositions |